Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs BioNTech SE - ADR — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $10.74, while BioNTech SE - ADR trades at $90.84 (market cap $23.14B). The key difference: BioNTech SE - ADR is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | BNTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $16.61 | $119.34 |
52-Week Low | $10.26 | $83.89 |
Market Cap | — | $23.14B |
Enterprise Value | — | $6.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $10.78 with no significant daily movement, showing neutral technical signals overall. The ETF maintains a consistent weekly dividend distribution strategy, though recent analyst commentary highlights concerns about NAV erosion despite high yields. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance levels cluster tightly around $10-11.
The outlook remains cautious as the synthetic option strategy delivers high income but exposes investors to amplified downside risk. While weekly distributions provide income appeal, total returns have lagged the underlying Amazon stock, creating sustainability concerns for long-term investors seeking both income and capital appreciation.
BNTX trades at $91.49, down 1.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $1.14 billion for 2025, with revenue of $2.87 billion, and is undergoing a strategic shift toward oncology, including a $1 billion share buyback and manufacturing site closures affecting 1,860 jobs. Analyst consensus is strongly bullish with a $129.67 price target.
The outlook hinges on BioNTech's transition from COVID-19 vaccine dependency to oncology pipeline success. Opportunities include a strong cash position of $16.78 billion and promising clinical data, but risks involve execution challenges, sustained losses, and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
